분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-06-18 15:46:16 , Hit : 1485
 AbbVie all-oral hepatitis C therapy gets rapid EU review


LONDON Tue Jun 17, 2014 2:23am EDT
0 Comments inShare14Share this
Email
Print

Related TopicsHealth »
LONDON (Reuters) - European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment.

The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.

AbbVie's regimen consists of protease inhibitor ABT-450, boosted by a widely used antiviral called ritonavir, combined with polymerase inhibitor dasabuvir, and NS5A inhibitor ombitasvir with or without the older antiviral drug ribavirin.

Gilead Sciences, which launched breakthrough hepatitis C drug Sovaldi in December, is slated to hear from U.S. regulators on its application for an all-oral regimen - which combines Sovaldi with experimental NS5A inhibitor ledipasvir - by early October.

Prior to Sovaldi's approval, hepatitis C needed to be treated for at least six months with a combination of pills and injections that could cause severe flu-like symptoms and other side effects that led many people to avoid or discontinue treatment.


(Reporting by Ben Hirschler; Editing by Sophie Walker)







907   핵심 암 유전자의 마스터 조절자 발견  이성욱 2014/07/01 1487
906   동맥경화의 새로운 표적을 발견  이성욱 2014/06/26 1750
905   A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi  이성욱 2014/06/25 1470
904   Perspective: The age of the phage  이성욱 2014/06/21 1855
903   노인성 황반변성의 혈관 증식을 저해하는 오메가-3 지방산  이성욱 2014/06/20 1871
  AbbVie all-oral hepatitis C therapy gets rapid EU review  이성욱 2014/06/18 1485
901   항체와 펩타이드로 구성된 펩티바디의 항암 효과  이성욱 2014/06/17 1789
900   AbbVie says hepatitis C regimen gets nod for FDA priority review  이성욱 2014/06/17 1493
899   간 재생의 새로운 모델  이성욱 2014/06/14 1750
898   낙타 젖에서 발견된 MERS 바이러스  이성욱 2014/06/14 2072
897   STAP 세포 관련 스캔들의 전말: 논문 기고에서 철회 결정까지  이성욱 2014/06/14 1867
896   남성 생식력에 부정적인 영향을 주는 핸드폰  이성욱 2014/06/14 1554
895   인간으로 진화이전에 이미 감염된 헤르페스  이성욱 2014/06/14 1896
894   BRCA 유전자 특허 무효판결 이후 1년: 거세져 가는 `암 유전자 데이터 공유`의 목소리  이성욱 2014/06/14 1974
893   암에서 마이크로RNA를 조절하는 새로운 초-보존 RNA 규명!  이성욱 2014/06/12 1581
892   야심찬 브레인 프로젝트  이성욱 2014/06/11 1680
891   간암 백신-어떻게 만들어야 효과적일까?  이성욱 2014/06/11 1704
890   Merck & Co to buy Idenix to boost hepatitis C drugs portfolio  이성욱 2014/06/11 1424
889   항생제 내성세균의 대안으로 부활하고 있는 박테리오파지 요법  이성욱 2014/06/06 2310
888   SARS 바이러스의 은폐 시스템을 무력화시키는 방법  이성욱 2014/06/06 1622

[이전 10개] [1]..[11][12][13][14][15][16][17][18] 19 [20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN